Shulman DeMeo Asset Management LLC Cuts Holdings in AstraZeneca PLC (NASDAQ:AZN)
Shulman DeMeo Asset Management LLC decreased its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 8,955 shares of the company’s stock after selling 359 shares during the period. Shulman DeMeo Asset Management LLC’s holdings in AstraZeneca were worth $448,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Sowell Financial Services LLC increased its holdings in AstraZeneca by 3.8% in the fourth quarter. Sowell Financial Services LLC now owns 50,650 shares of the company’s stock valued at $2,614,000 after buying an additional 1,862 shares during the last quarter. Diversified Trust Co bought a new stake in AstraZeneca in the fourth quarter valued at about $647,000. Trust Co. of Toledo NA OH bought a new stake in AstraZeneca in the fourth quarter valued at about $251,000. New England Research & Management Inc. increased its holdings in AstraZeneca by 273.5% in the fourth quarter. New England Research & Management Inc. now owns 21,475 shares of the company’s stock valued at $1,074,000 after buying an additional 15,725 shares during the last quarter. Finally, Private Trust Co. NA increased its holdings in AstraZeneca by 4.2% in the fourth quarter. Private Trust Co. NA now owns 7,468 shares of the company’s stock valued at $373,000 after buying an additional 298 shares during the last quarter. Institutional investors own 15.57% of the company’s stock.
Several brokerages recently weighed in on AZN. AlphaValue raised AstraZeneca to a “reduce” rating in a report on Wednesday, December 30th. Morgan Stanley raised AstraZeneca from an “equal weight” rating to an “overweight” rating in a report on Monday, December 7th. Oddo Bhf raised AstraZeneca from a “reduce” rating to a “buy” rating in a report on Wednesday, September 23rd. Piper Sandler lowered their target price on AstraZeneca from $179.00 to $175.00 and set an “overweight” rating for the company in a report on Sunday, December 13th. Finally, Berenberg Bank initiated coverage on AstraZeneca in a report on Tuesday, September 29th. They set a “buy” rating for the company. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $83.80.
AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.47 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.49 by ($0.02). The business had revenue of $6.58 billion for the quarter, compared to analyst estimates of $6.54 billion. AstraZeneca had a return on equity of 37.23% and a net margin of 9.65%. On average, analysts expect that AstraZeneca PLC will post 2 EPS for the current fiscal year.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases.
Recommended Story: The components of the Stochastic Momentum Index
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.